Skip to main content

Advertisement

SpringerLink
Log in

Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report

  • Report of the committee
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

The Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer published its first report in July 2013 on the epidemiological assessment of the associations of diabetes with cancer risk/prognosis, the common risk factors for diabetes and cancer, and cancer risk associated with diabetes treatment The JDS/JCA Joint Committee continued its work to assess the role of glycemic control in the development of cancer in patients with diabetes. This review shows that high-quality evidence examining the association between glycemic control and cancer risk is lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goto A, Noto H, Noda M, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer, Second Report. J Japan Diabetes Soc. 2016;59(3):174–77. doi:10.11213/tonyobyo.59.174 (In Japanese)

    Google Scholar 

  2. Kasuga M, Ueki K, Tajima N, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetol Int. 2013;4(2):81–96.

    Article  Google Scholar 

  3. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract. 2011;17(4):616–28.

    Article  PubMed  Google Scholar 

  4. Sasazuki S, Charvat H, Hara A, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104(11):1499–507.

    Article  CAS  PubMed  Google Scholar 

  5. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.

    Article  PubMed  Google Scholar 

  6. Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia. 2011;54(7):1608–14.

    Article  CAS  PubMed  Google Scholar 

  7. Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.

    Article  Google Scholar 

  8. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011;54(1):25–31.

    Article  CAS  PubMed  Google Scholar 

  9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352(9131):837–53.

    Article  Google Scholar 

  10. UK Prospective Diabetes Study. UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet. 1998;352(9131):854–65.

    Article  Google Scholar 

  11. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.

    Article  PubMed Central  Google Scholar 

  12. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterrans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.

    Article  CAS  PubMed  Google Scholar 

  13. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.

    Article  CAS  PubMed  Google Scholar 

  14. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35.

    Article  CAS  PubMed  Google Scholar 

  15. Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010;59(5):1254–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Miao Jonasson J, Cederholm J, Eliasson B, Zethelius B, Eeg-Olofsson K, Gudbjornsdottir S. HbA1C and cancer risk in patients with type 2 diabetes–a nationwide population-based prospective cohort study in Sweden. PLoS One. 2012;7(6):e38784.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Onitilo AA, Stankowski RV, Berg RL, et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev. 2014;23(2):134–40.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tokyo Women’s Medical University, Tokyo, Japan

    Atsushi Goto

  2. St. Luke’s International Hospital, Tokyo, Japan

    Hiroshi Noto

  3. Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan

    Mitsuhiko Noda

  4. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

    Kohjiro Ueki

  5. National Center for Global Health and Medicine, Tokyo, Japan

    Masato Kasuga

  6. Jikei University School of Medicine, Tokyo, Japan

    Naoko Tajima

  7. Department of General Internal Medicine, Dentistry, and Oncologic Emergencies, National Cancer Center Hospital, Tokyo, Japan

    Ken Ohashi

  8. Department of Biochemistry, Kitasato University School of Medicine, Sagamihara, Japan

    Ryuichi Sakai

  9. National Cancer Center Research Center for Cancer Prevention and Screening, Tokyo, Japan

    Shoichiro Tsugane

  10. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Nobuyuki Hamajima

  11. Department of Public Health and Occupational Medicine, Mie University Graduate School of Medicine, Tsu, Japan

    Kazuo Tajima

  12. Center for Antibody and Vaccine Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Kohzoh Imai

  13. National Cancer Center Research Institute, Tokyo, Japan

    Hitoshi Nakagama

Authors
  1. Atsushi Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Noto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitsuhiko Noda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kohjiro Ueki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masato Kasuga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoko Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ken Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ryuichi Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shoichiro Tsugane
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nobuyuki Hamajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kazuo Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kohzoh Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hitoshi Nakagama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kohjiro Ueki.

Ethics declarations

Conflict of interest

Hiroshi Noto received honoraria for manuscripts from Eli Lilly Japan K.K. Mitsuhiko Noda received scholarship grants from Takeda Pharmaceutical Company Limited and AstraZeneca K. K. Kohjiro Ueki received speaker honoraria from MSD K.K, scholarship grants from Takeda Pharmaceutical Company Limited, Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Astellas Pharma Inc., Sanofi K. K, Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K, MSD K.K, Boehringer Ingelheim, Mitsubishi-Tanabe Pharma Corporation and courses endowed by MSD K.K, Boehringer Ingelheim and Novo Nordisk Pharma Ltd. Naoko Tajima received speaker honoraria from Astellas Pharma Inc., MSD K.K, Kissei Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly Japan K.K, Boehringer Ingelheim and Novo Nordisk Pharma Ltd. Nobuyuki Hamajima received scholarship grants from Sugi Drugstore Co. Ltd. Kohzoh Imai received research grants from DeNA Life Science. Inc. Hitoshi Nakagama received research grants from Shimadzu Corporation and BioMimetics Sympathies Inc. Atsushi Goto, Masato Kasuga, Ken Ohashi, Ryuichi Sakai, Shoichiro Tsugane and Kazuo Tajima declare that they have no conflict of interest.

Additional information

In 2014, the Japan Diabetes Society (JDS) and the Japanese Cancer Association (JCA) restarted the JDS/JCA Joint Committee on Diabetes and Cancer, which published the second committee report in Japanese [1]. This is the English version of that report.

This article has been jointly published in Diabetology International and Cancer Science (doi:10.1111/cas.12889) by the Japan Diabetes Society and the Japanese Cancer Association.

Appendix

Appendix

The following authors are members of the Japan Diabetes Society: Mitsuhiko Noda, Kohjiro Ueki, Masato Kasuga, Naoko Tajima, and Ken Ohashi.

Editorial Collaborators: Atsushi Goto and Hiroshi Noto.

The following authors are members of the Japanese Cancer Association: Ryuichi Sakai, Shoichiro Tsugane, Nobuyuki Hamajima, Kazuo Tajima, Kohzoh Imai, and Hitoshi Nakagama.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goto, A., Noto, H., Noda, M. et al. Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report. Diabetol Int 7, 12–15 (2016). https://doi.org/10.1007/s13340-016-0257-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-016-0257-z

Keywords

Search

Navigation